Royalty Pharma PLC expected to post earnings of $1.27 a share - Earnings Preview

Royalty Pharma

05/05/2023 19:37

* Royalty Pharma PLC  RPRX.OQ   RPRX.O  is expected to show
a rise
in quarterly revenue when it reports  results on May 9. 
    * The New York City-based  company is expected to report  a
51.7% increase in revenue to $852.904 million from $562.05
million a year ago, according to the mean estimate from 4
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Royalty Pharma PLC
is for
earnings of $1.27 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 9 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had fallen by
about 3.1%
in the last three months. ​
    * Wall Street's median 12-month price target for Royalty
Pharma
PLC is $51​, above​ its last closing price of $34.89. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2022  1.39        1.47       1.56      Beat    5.9
 Sep. 30 2022  0.71        0.72       0.72      Met     0.5
 Jun. 30 2022  0.79        0.78       0.79      Beat    1.1​
 Mar. 31 2022  0.74        0.73       0.60      Missed  -18
 ​​Dec.        0.77        0.78       0.80      Beat    3.2
 31 2021                                                
 Sep. 30 2021  0.68        0.69       0.17      Missed  -75.4​
 Jun. 30 2021  0.69        0.70       1.08      Beat    55.4
 Mar. 31 2021  0.65        0.65       0.18      Missed  -72.3
 This summary was machine generated May 5 at 18:36 GMT.  All
figures in US dollars  unless otherwise stated